Scheduling Nab-Paclitaxel with Gemcitabine (Siege): Randomised Phase Ii Trial to Investigate Two Different Schedules of Nab-Paclitaxel (Abx) Combined with Gemcitabine (Gem) As First Line Treatment for Metastatic Pancreatic Adenocarcinoma (Pdac)

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)

European Journal of Cancer ◽

10.1016/j.ejca.2014.09.015 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3116-3124 ◽

Cited By ~ 15

Author(s):

Isabelle Trouilloud ◽

Anne-Claire Dupont-Gossard ◽

David Malka ◽

Pascal Artru ◽

Mélanie Gauthier ◽

...

Keyword(s):

Dose Rate ◽

Phase Ii ◽

Phase Ii Study ◽

Fixed Dose ◽

Line Treatment ◽

First Line ◽

Fixed Dose Rate ◽

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

European Journal of Cancer ◽

10.1016/j.ejca.2020.05.018 ◽

2020 ◽

Vol 136 ◽

pp. 25-34

Author(s):

Yves Rinaldi ◽

Anne-Laure Pointet ◽

Faiza Khemissa Akouz ◽

Karine Le Malicot ◽

Bidaut Wahiba ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Cancérologie Digestive ◽

Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma ( GATE 1)

International Journal of Cancer ◽

10.1002/ijc.33225 ◽

2020 ◽

Vol 148 (3) ◽

pp. 682-691

Author(s):

Eric Assenat ◽

Laurent Mineur ◽

Caroline Mollevi ◽

Evelyne Lopez‐Crapez ◽

Catherine Lombard‐Bohas ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.194 ◽

2015 ◽

Vol 137 ◽

pp. 79

Author(s):

N.D. Fleming ◽

R.L. Coleman ◽

C.S. Tung ◽

M.F. Munsell ◽

A.K. Sood

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

First Line ◽

Dose Dense ◽

P48.09 Anlotinib Plus Etoposide and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Single Arm Phase II Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.01.879 ◽

2021 ◽

Vol 16 (3) ◽

pp. S503

Author(s):

B. Han ◽

W. Zhang ◽

B. Zhang ◽

Y. Chen ◽

Y. Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Extensive Stage ◽

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

XELIRINOX Regimen a Triple Combination of XELoda, IRINotecan and OXaliplatin in First-line Treatment of Metastatic Pancreatic Adenocarcinoma

Cancer and Oncology Research ◽

10.13189/cor.2020.060101 ◽

2020 ◽

Vol 6 (1) ◽

pp. 1-9

Author(s):

Haider Y. Shukur

Keyword(s):

Line Treatment ◽

Triple Combination ◽

First Line ◽

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Cited By ~ 1

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Cited By ~ 83

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽